search
Back to results

Traxi Panniculus Retractor for Cesarean Delivery

Primary Purpose

Obesity, Morbid, Cesarean Section Complications

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Traxi panniculus retraction (Clinical Innovations, LLC)
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Obesity, Morbid

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pregnant
  • BMI greater than or equal to 40 kg/m^2
  • Undergoing non-emergent cesarean delivery
  • Able and willing to provide written, informed consent
  • Singleton gestation

Exclusion Criteria:

  • Fetal demise
  • Disruption of abdominal skin (infection, rash, abrasion, laceration)
  • Known adhesive allergy

Sites / Locations

  • Beth Israel Deaconess Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Traxi panniculus retraction group

Standard of care

Arm Description

The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.

Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)

Outcomes

Primary Outcome Measures

Cesarean delivery operative time
time from skin incision to closure during cesarean delivery

Secondary Outcome Measures

Change in pulmonary function (forced vital capacity)
measure difference in pulmonary function tests (FVC=forced vital capacity) before and after application of panniculus retraction method
Change in pulmonary function (forced expiratory volume)
measure difference in pulmonary function tests (FEV1=forced expiratory volume in 1 minute) before and after application of panniculus retraction method
Patient satisfaction assessed by a questionnaire
patient-reported outcomes regarding surgery and delivery will be obtained using a survey made by the research team with a four level likert scale
Provider satisfaction with a survey
provider-reported outcomes regarding surgery will be obtained using survey with an eleven level likert scale

Full Information

First Posted
July 18, 2018
Last Updated
January 10, 2023
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Clinical Innovations, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT03651076
Brief Title
Traxi Panniculus Retractor for Cesarean Delivery
Official Title
Randomized Controlled Trial of Panniculus Retraction Methods for Cesarean Delivery
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 2, 2018 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Clinical Innovations, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This prospective, open-label, randomized-controlled trial is designed to evaluate the use of the Traxi panniculus retractor-- a commercially available Class I FDA-exempt device will improve surgical outcomes, cardiopulmonary function, and provider/patient satisfaction in morbidly obese women undergoing cesarean delivery.
Detailed Description
Morbidly obese women (BMI >/= 40) undergoing non-emergent cesarean delivery will be recruited and randomized to Traxi panniculus retraction or standard of care for panniculus retraction. The primary outcome evaluated will be operating time (incision to closure). Other secondary outcomes related to surgery including estimated blood loss, surgical site infection, and number of scrubbed personnel. A secondary aim of the study is to evaluate the hypothesis that the Traxi retraction device reduces chestwall compression panniculus retraction and will improve intraoperative pulmonary function. To do this, the investigators will measure the difference in individual participant pulmonary function tests (forced vital capacity, forced expiratory volume) before and after panniculus retraction using a bedside spirometer. A tertiary aim of the study is to evaluate the hypothesis that the Traxi retraction device will improve patient and provider satisfaction due to improved delivery experience and maintaining patient dignity. Patient and provider-reported outcomes will be evaluated using surveys.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid, Cesarean Section Complications

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Traxi panniculus retraction group
Arm Type
Experimental
Arm Description
The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
Arm Title
Standard of care
Arm Type
No Intervention
Arm Description
Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
Intervention Type
Device
Intervention Name(s)
Traxi panniculus retraction (Clinical Innovations, LLC)
Intervention Description
class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
Primary Outcome Measure Information:
Title
Cesarean delivery operative time
Description
time from skin incision to closure during cesarean delivery
Time Frame
through study completion, approximately 6 to 8 weeks
Secondary Outcome Measure Information:
Title
Change in pulmonary function (forced vital capacity)
Description
measure difference in pulmonary function tests (FVC=forced vital capacity) before and after application of panniculus retraction method
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Change in pulmonary function (forced expiratory volume)
Description
measure difference in pulmonary function tests (FEV1=forced expiratory volume in 1 minute) before and after application of panniculus retraction method
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Patient satisfaction assessed by a questionnaire
Description
patient-reported outcomes regarding surgery and delivery will be obtained using a survey made by the research team with a four level likert scale
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Provider satisfaction with a survey
Description
provider-reported outcomes regarding surgery will be obtained using survey with an eleven level likert scale
Time Frame
through study completion, approximately 6 to 8 weeks
Other Pre-specified Outcome Measures:
Title
Estimated blood loss
Description
estimated blood loss reported on operative report
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Wound complication
Description
review of medical records for 6 weeks postpartum to evaluate for wound opening or infection rates
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Number of personnel involved in cesarean
Description
recorded number of scrubbed personnel needed to assist with surgery
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Hospital length of stay
Description
inpatient length of stay post-delivery
Time Frame
through study completion, approximately 6 to 8 weeks
Title
Composite neonatal outcome
Description
composite rate of neonatal intensive care unit (NICU) admission, 5-minute Apgar score <7)
Time Frame
through study completion, approximately 6 to 8 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pregnant BMI greater than or equal to 40 kg/m^2 Undergoing non-emergent cesarean delivery Able and willing to provide written, informed consent Singleton gestation Exclusion Criteria: Fetal demise Disruption of abdominal skin (infection, rash, abrasion, laceration) Known adhesive allergy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ai-ris Y Collier, MD
Phone
6176671726
Email
acollier@bidmc.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Dzinoreva
Phone
6176670837
Email
mdzinore@bidmc.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ai-ris Collier, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Traxi Panniculus Retractor for Cesarean Delivery

We'll reach out to this number within 24 hrs